Skip to main content

Table 5 Progression-free survival and time to next antilymphoma treatment in the rituximab versus “watch-and-wait” study

From: Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients?

 

PNRNT 3 years

Differences between arms

HR p value

PFS 3 years

Differences between arms

HR p value

W&W

48%

Rx4 vs W&W

0.37 p < 0.001

33%

Rx4 vs W&W

0.46 p < 0.001

Rx4

80%

Rx4 + RM vs W&W

0.20 p < 0.001

60%

Rx4 + RM vs W&W

0.21 p < 0.001

Rx4 + RM

91%

Rx4 + RM vs Rx4

0.57 p = 0.10

81%

Rx4 + RM vs Rx4

0.43 p < 0.001

  1. PNRNT: patients not receiving next therapy; PFS: progression free survival; HR: hazard ratio ; W&W: watch and wait; Rx4: four weekly doses of rituximab; Rx4 + RM: four weekly doses of rituximab plus rituximab maintenance.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us